Mylan hopes to stop Watson launch of diabetes drug
PITTSBURGH — Mylan is challenging a federal court decision ordering the Food and Drug Administration to allow Watson Pharmaceuticals to launch a generic diabetes drug, Mylan said.
The generic drug maker said it filed a motion in the U.S. District Court for the District of Columbia Tuesday to stay the court’s order, which called on the FDA to let Watson launch a generic version of Takeda’s Type 2 diabetes drug Actos (pioglitazone).
"Mylan is disappointed in yesterday’s ruling regarding pioglitazone, and we believe the court erred in its decision by directly contravening the Hatch-Waxman Act," Mylan CEO Heather Bresch said, referring to the 1984 law that created an abbreviated approval pathway for generic pharmaceutical drugs. "Mylan does not believe Watson is entitled to participate in Mylan’s 180-day exclusivity period in relation to this product, and we intend to pursue this case vigorously, including seeking expedited relief from the appellate court if necessary."
Watson filed suit against the FDA in August 2012, alleging that an agency decision to deny Watson’s claim to shared exclusivity in marketing a generic version of Actos would improperly delay its launch of the drug.
Actos had sales of about $2.7 billion during the 12-month period ended in May, according to IMS Health.
Catamaran gets $60 million in contracts from Indiana Medicaid program
LISLE, Ill. — Pharmacy benefit manager Catamaran has won contracts with Indiana’s state Medicaid program, the company said.
Catamaran said it was awarded the contracts, worth $60 million, to provide implementation, adjudication and PBM services to the program for six years, not including two one-year options. Catamaran will provide what it called a flexible and customized suite of PBM services, including implementation, claims processing, clinical and technical call center services, electronic prescribing, federal and supplemental rebate administration, pharmacy audits, specialty medication management and "enhanced" coordination of benefits, among others. The services will start on April 1, 2013.
"Catamaran is building incredible momentum around creating tailored, innovative PBM solutions for state governments seeking to reduce healthcare costs, simplify the delivery of medicine and improve the health of their beneficiaries," Catamaran chairman and CEO Mark Thierer said. "As a consultative partner to the state of Indiana, Catamaran will provide services and technology solutions to streamline the program and avoid the costly events that the right medicine or intervention can deter."
Navarro Discount Pharmacy supplies pink Rx bottles in support of Breast Cancer Awareness month
MIAMI and PEMBROKE PINES, Fla. — Regional pharmacy chain Navarro Discount Pharmacy, which operates 31 locations in south Florida, is supplying pink prescription bottle caps on all prescriptions filled during the month of October in support of Breast Cancer Awareness month, the company has announced.
“As a community pharmacy, we are focused on supporting activities that educate women, families and children about a variety of health issues,” stated Albert Garcia, EVP pharmacy operations at Navarro Discount Pharmacy.
The company supports and participates in several major breast cancer awareness charitable organizations, including the Susan B. Komen Foundation and the Liga Contra el Cancer (The League Against Cancer).
“Breast cancer is one of the leading causes of cancer death among women of all races, including Hispanic origin populations,” stated Cristy Leon-Rivero, VP marketing at Navarro Discount Pharmacy.
In addition to the pink prescription bottle caps, Navarro is using this as an opportunity to remind women to be aware and proactive in an effort to detect breast cancer earlier by conducting their own self-examinations. Breast cancer affects 1-out-of-8 women during their lives. It is the second-leading cancer killer of women in the United States, next to lung cancer. Thanks to screening and detection, breast cancer often can be found early, when the chance of successful treatment is highest.